Information Provided By: 
Fly News Breaks for November 20, 2019
CHRS
Nov 20, 2019 | 06:07 EDT
October Symphony data show continued share gains for Coherus Biosciences' Udenyca in the pegfilgrastim market, with unit share reaching 20.4%, Barclays analyst Balaji Prasad tells investors in a research note. This represents another positive data point for Udenyca uptake, but investors are still anxiously awaiting the impact of Sandoz's Ziextenzo launch, adds the analyst. He reiterates Coherus as a top pick with an Overweight rating and $31 price target.
News For CHRS From the Last 2 Days
There are no results for your query CHRS
